How much did Replicel Life Sciences achieve in EBIT for the current year?
In the current year, Replicel Life Sciences has achieved an EBIT of -1.4 M CAD.
Replicel Life Sciences EBIT 2024
Replicel Life Sciences EBIT
-1.4 M CAD
Ticker
RP.V
ISIN
CA76027P4006
WKN
A2APX7
In 2024, Replicel Life Sciences's EBIT was -1.4 M CAD, a -39.36% increase from the -2.3 M CAD EBIT recorded in the previous year.
The Replicel Life Sciences EBIT history
| YEAR | EBIT (undefined CAD) |
|---|---|
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
| 2011 | - |
| 2010 | - |
| 2009 | - |
| 2008 | - |
| 2007 | - |
| 2006 | - |
Replicel Life Sciences Revenue, EBIT, Net Income CA76027P4006 · A2APX7
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Replicel Life Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Replicel Life Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Replicel Life Sciences’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Replicel Life Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Replicel Life Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Replicel Life Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Replicel Life Sciences’s growth potential.
Replicel Life Sciences Revenue, EBIT and net profit per share
| Date | Replicel Life Sciences Revenue | Replicel Life Sciences EBIT | Replicel Life Sciences Net Income |
|---|---|---|---|
| 2022 | 353,740 undefined | -1.4 M undefined | -743,230 undefined |
| 2021 | 353,740 undefined | -2.3 M undefined | -4.07 M undefined |
| 2020 | 353,740 undefined | -1.35 M undefined | -1.58 M undefined |
| 2019 | 353,740 undefined | -2.93 M undefined | -3 M undefined |
| 2018 | 121,110 undefined | -2.74 M undefined | -2.77 M undefined |
| 2017 | 0 undefined | -5.99 M undefined | -6.01 M undefined |
| 2016 | 0 undefined | -4.29 M undefined | -4.27 M undefined |
| 2015 | 0 undefined | -5.05 M undefined | -5.04 M undefined |
| 2014 | 0 undefined | 0 undefined | 0 undefined |
| 2013 | 0 undefined | 0 undefined | 0 undefined |
| 2012 | 0 undefined | -4.47 M undefined | -3.36 M undefined |
| 2011 | 0 undefined | -3.73 M undefined | -3.71 M undefined |
| 2010 | 0 undefined | -2.54 M undefined | -2.54 M undefined |
| 2009 | 0 undefined | -560,000 undefined | -560,000 undefined |
| 2008 | 0 undefined | -20,000 undefined | -20,000 undefined |
| 2007 | 0 undefined | -380,000 undefined | -450,000 undefined |
| 2006 | 0 undefined | -490,000 undefined | -430,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2006 | 0 CAD | -490,000 CAD | -430,000 CAD |
| 2007 | 0 CAD | -380,000 CAD | -450,000 CAD |
| 2008 | 0 CAD | -20,000 CAD | -20,000 CAD |
| 2009 | 0 CAD | -560,000 CAD | -560,000 CAD |
| 2010 | 0 CAD | -2.54 M CAD | -2.54 M CAD |
| 2011 | 0 CAD | -3.73 M CAD | -3.71 M CAD |
| 2012 | 0 CAD | -4.47 M CAD | -3.36 M CAD |
| 2013 | 0 CAD | 0 CAD | 0 CAD |
| 2014 | 0 CAD | 0 CAD | 0 CAD |
| 2015 | 0 CAD | -5.05 M CAD | -5.04 M CAD |
| 2016 | 0 CAD | -4.29 M CAD | -4.27 M CAD |
| 2017 | 0 CAD | -5.99 M CAD | -6.01 M CAD |
| 2018 | 121,110 CAD | -2.74 M CAD | -2.77 M CAD |
| 2019 | 353,740 CAD | -2.93 M CAD | -3 M CAD |
| 2020 | 353,740 CAD | -1.35 M CAD | -1.58 M CAD |
| 2021 | 353,740 CAD | -2.3 M CAD | -4.07 M CAD |
| 2022 | 353,740 CAD | -1.4 M CAD | -743,230 CAD |
Replicel Life Sciences stock margins CA76027P4006 · A2APX7
The Replicel Life Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Replicel Life Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Replicel Life Sciences.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Replicel Life Sciences's sales revenue. A higher gross margin percentage indicates that the Replicel Life Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Replicel Life Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Replicel Life Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Replicel Life Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Replicel Life Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Replicel Life Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Replicel Life Sciences Margin History
| Replicel Life Sciences Gross margin | Replicel Life Sciences Profit margin | Replicel Life Sciences EBIT margin | Replicel Life Sciences Profit margin |
|---|---|---|---|
| 2022 | 100.07 % | -394.5 % | -210.11 % |
| 2021 | 100.07 % | -650.57 % | -1,151.5 % |
| 2020 | 100.07 % | -381.74 % | -446.74 % |
| 2019 | 100.07 % | -827.4 % | -849.26 % |
| 2018 | 100.07 % | -2,261.83 % | -2,286.42 % |
| 2017 | 100.07 % | 0 % | 0 % |
| 2016 | 100.07 % | 0 % | 0 % |
| 2015 | 100.07 % | 0 % | 0 % |
| 2014 | 100.07 % | 0 % | 0 % |
| 2013 | 100.07 % | 0 % | 0 % |
| 2012 | 100.07 % | 0 % | 0 % |
| 2011 | 100.07 % | 0 % | 0 % |
| 2010 | 100.07 % | 0 % | 0 % |
| 2009 | 100.07 % | 0 % | 0 % |
| 2008 | 100.07 % | 0 % | 0 % |
| 2007 | 100.07 % | 0 % | 0 % |
| 2006 | 100.07 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2006 | 100.07 % | 0 % | 0 % |
| 2007 | 100.07 % | 0 % | 0 % |
| 2008 | 100.07 % | 0 % | 0 % |
| 2009 | 100.07 % | 0 % | 0 % |
| 2010 | 100.07 % | 0 % | 0 % |
| 2011 | 100.07 % | 0 % | 0 % |
| 2012 | 100.07 % | 0 % | 0 % |
| 2013 | 100.07 % | 0 % | 0 % |
| 2014 | 100.07 % | 0 % | 0 % |
| 2015 | 100.07 % | 0 % | 0 % |
| 2016 | 100.07 % | 0 % | 0 % |
| 2017 | 100.07 % | 0 % | 0 % |
| 2018 | 100.07 % | -2,261.83 % | -2,286.42 % |
| 2019 | 100.07 % | -827.4 % | -849.26 % |
| 2020 | 100.07 % | -381.74 % | -446.74 % |
| 2021 | 100.07 % | -650.57 % | -1,151.5 % |
| 2022 | 100.07 % | -394.5 % | -210.11 % |
Replicel Life Sciences Aktienanalyse
What does Replicel Life Sciences do?
Replicel Life Sciences Inc was founded in Canada in 2010 with the goal of developing cutting-edge technologies for the regeneration of body tissues. The company operates in the biotechnology, medical, and pharmaceutical fields and works closely with leading scientists and research groups. The business model of Replicel is based on the research and development of regenerative medicine, which builds on stem cell research and tissue engineering technologies. The aim is to develop new treatment options for diseases and injuries in which the body is unable to heal itself. The company has several divisions, including Replicel Cell Therapy, Replicel Skin rejuvenation, Replicel tendon regeneration, and RepliCel Hair regeneration. Each of these business areas focuses on researching specific technologies for regenerating cells and tissues in different parts of the body. Replicel Cell Therapy is developing therapies for the treatment of diseases such as arthritis, tendinitis, and joint pain. These therapies are based on stem cell research and the body's ability to regenerate damaged cells and restore healthy tissue. Replicel Skin rejuvenation focuses on the development of therapies for skin rejuvenation. The technology is based on the use of stem cells to repair damaged skin cells and promote the growth of new, healthy cells. This can improve the elasticity and firmness of the skin and help reduce wrinkles and other signs of aging. Replicel tendon regeneration is developing therapies for the treatment of tendon injuries. These injuries are often difficult to treat and can lead to long-term damage. Replicel uses its stem cell technology to repair damaged tendon cells and restore healthy, functional tissue. RepliCel Hair regeneration is developing therapies for the treatment of hair loss. The technology is based on the use of stem cells to repair damaged hair follicles and promote new hair growth. The therapy offers an alternative to traditional hair transplants and can be used in both men and women. Replicel has several products in development, including RCH-01 and RCS-01. RCH-01 is a therapy for the treatment of hair loss in men and women. The therapy is based on the use of stem cells to repair damaged hair follicles and promote new hair growth. RCS-01 is a therapy for skin rejuvenation and wrinkles. The therapy is based on the use of stem cells to promote the production of collagen and elastin in the skin. Over the years, Replicel has entered into several important partnerships and funding agreements. In 2013, the company signed an agreement with Shiseido, a leading company in the cosmetics industry. Shiseido participated in the development of RCH-01 and RCS-01 and funded the clinical trials. In 2016, Replicel received $5.5 million in funding from the Canadian government to advance the development of its stem cell technologies. Overall, Replicel Life Sciences Inc is a leading company in the field of regenerative medicine. Through its collaboration with leading scientists and researchers, the company has developed innovative technologies that can be used to treat diseases and injuries. With products like RCH-01 and RCS-01, Replicel has the potential to improve the lives of millions of people worldwide. Replicel Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Replicel Life Sciences's EBIT
Replicel Life Sciences's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Replicel Life Sciences's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Replicel Life Sciences's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Replicel Life Sciences’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Replicel Life Sciences stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Replicel Life Sciences.
How has the EBIT of Replicel Life Sciences developed in recent years?
The EBIT of Replicel Life Sciences has increased by -39.36% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Replicel Life Sciences?
The EBIT of Replicel Life Sciences is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Replicel Life Sciences pay?
Over the past 12 months, Replicel Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Replicel Life Sciences is expected to pay a dividend of 0 CAD.
What is the dividend yield of Replicel Life Sciences?
The current dividend yield of Replicel Life Sciences is .
When does Replicel Life Sciences pay dividends?
Replicel Life Sciences pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Replicel Life Sciences?
Replicel Life Sciences paid dividends every year for the past 0 years.
What is the dividend of Replicel Life Sciences?
For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Replicel Life Sciences located?
Replicel Life Sciences is assigned to the 'Health' sector.
Wann musste ich die Aktien von Replicel Life Sciences kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Replicel Life Sciences from 9/21/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.
When did Replicel Life Sciences pay the last dividend?
The last dividend was paid out on 9/21/2024.
What was the dividend of Replicel Life Sciences in the year 2023?
In the year 2023, Replicel Life Sciences distributed 0 CAD as dividends.
In which currency does Replicel Life Sciences pay out the dividend?
The dividends of Replicel Life Sciences are distributed in CAD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Replicel Life Sciences
Our stock analysis for Replicel Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Replicel Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Replicel Life Sciences Revenue
- Replicel Life Sciences Net Income
- Replicel Life Sciences P/E
- Replicel Life Sciences P/S
- Replicel Life Sciences EBIT
- Replicel Life Sciences Dividend
- Replicel Life Sciences Stocks
- Replicel Life Sciences Market capitalization
- Replicel Life Sciences Debt
- Replicel Life Sciences Liabilities
- Replicel Life Sciences Equity
- Replicel Life Sciences AAQS
- Replicel Life Sciences Employees
- Replicel Life Sciences ROE
- Replicel Life Sciences ROA
- Replicel Life Sciences ROCE
